common
cold
virus
induc
profound
inflammatori
respons
airway
mucosa
immun
reaction
lead
releas
differ
inflammatori
substanc
thought
play
major
role
gener
symptom
diseas
demonstr
patient
common
cold
inflamm
paranas
sinus
shown
comput
tomographi
recent
shown
intranas
administ
steroid
benefici
effect
adjunct
therapi
acut
sinus
optim
therapi
common
cold
may
therefor
attack
arm
infect
viru
replic
inflammatori
respons
suggest
viral
bronchiol
pneumonia
saliva
essenti
mainten
ecolog
balanc
oral
caviti
consid
essenti
part
mucos
host
defens
system
one
major
function
system
inhibit
adher
pathogen
bacteria
oral
tissu
mechan
immunolog
nonimmunolog
mean
addit
human
mouth
import
rout
viral
transmiss
saliva
salivari
compon
neutral
virus
herp
simplex
viru
type
human
immunodefici
viru
type
respiratori
syncyti
viru
echoviru
fluticason
propion
new
topic
activ
glucocorticosteroid
high
topic
activ
low
bioavail
hypothes
drug
would
reliev
symptom
virusinduc
rhiniti
howev
cough
symptom
could
find
benefici
effect
extend
find
studi
analyz
salivari
flow
rate
select
major
host
antimicrobi
compon
present
whole
saliva
patient
common
cold
consid
import
human
mouth
one
main
rout
entri
virus
bacteria
human
bodi
studi
part
larg
clinic
trial
examin
effect
fluticason
propion
treatment
common
cold
two
hundr
patient
particip
treatment
studi
patient
random
object
purpos
investig
studi
effect
potent
topic
steroid
fluticason
propion
patient
earli
sign
symptom
common
cold
character
mucos
inflammatori
respons
salivari
defens
factor
flow
rate
patient
analyz
studi
design
forti
patient
symptom
common
cold
random
group
receiv
either
highdos
fluticason
propion
per
nostril
placebo
time
daili
day
paraffinstimul
whole
saliva
collect
day
onset
medic
day
posttreat
day
followup
result
salivari
flow
rate
innat
host
defens
factor
total
protein
content
affect
common
cold
iga
increas
day
day
p
student
test
rel
proport
salivari
peroxidas
iga
increas
day
p
day
p
patient
receiv
fluticason
saliva
flow
rate
lower
day
p
day
innat
salivari
defens
factor
affect
iga
increas
day
p
day
p
comparison
day
present
investig
forti
student
male
femal
least
year
age
healthi
last
week
symptom
develop
upper
respiratori
tract
infect
common
cold
hour
basi
earlier
experienceeg
sore
throat
nasal
discharg
nasal
obstruct
cough
excess
sneezingwer
recruit
studi
patient
histori
hour
acut
upper
respiratori
infect
requir
concomit
medic
major
septum
deviat
nasal
polyposi
recurr
chronic
sinus
pregnanc
exclud
patient
random
group
fluticason
group
ft
group
includ
male
femal
patient
mean
age
year
common
cold
group
cc
group
includ
male
femal
patient
mean
age
year
ft
group
receiv
puff
per
nostril
fluticason
propion
time
day
cc
group
receiv
puff
per
nostril
placebo
prepar
time
day
high
dose
exceed
usual
select
reach
maxim
assum
effect
exist
safeti
data
earli
shortterm
trial
fluticason
propion
show
microgram
per
day
could
administ
without
side
effect
investig
approv
ethic
committe
medic
faculti
univers
turku
studi
medic
administ
mean
meter
dose
sprayer
similar
size
shape
composit
except
fluticason
propion
ingredi
benzalkonium
chlorid
phenylethyl
alcohol
dextros
microcrystallin
cellulos
carboxymethylcellulos
sodium
polysorb
purifi
water
medic
given
doubleblind
manner
start
first
visit
continu
day
patient
attend
clinic
depart
pediatr
turku
univers
hospit
time
studi
saliva
sampl
collect
follow
appoint
day
onset
medic
day
day
last
administr
posttreat
day
day
first
visit
followup
method
microbi
etiolog
result
treatment
studi
publish
briefli
nasopharyng
specimen
collect
day
diagnosi
virus
present
mucu
antigen
detect
viru
cultur
polymeras
chain
reaction
rhinovirus
addit
blood
sampl
assess
day
pair
viral
igg
serolog
swab
nasopharyng
mucu
cultur
blood
chocol
agar
plate
detect
betahemolyt
streptococci
haemophilu
influenza
branhamella
catarrhali
result
group
present
studi
shown
tabl
paraffinstimul
whole
saliva
collect
standard
way
minut
particip
collect
volum
determin
quantit
flow
rate
particip
allow
use
drug
refrain
smoke
eat
drink
hour
saliva
collect
saliva
sampl
store
ice
centrifug
within
hour
sorval
superspe
centrifug
minut
aliquot
centrifug
saliva
need
analysi
divid
separ
tube
store
analyz
total
protein
concentr
measur
accord
method
lowri
et
al
bovin
serum
albumin
sigma
chemic
co
st
loui
mo
use
standard
lysozym
activ
estim
micrococcu
lysodeikticu
diffus
plate
lysozym
kit
kallestad
laboratori
chaska
minn
lyophil
human
urin
lysozym
use
standard
salivari
peroxidas
myeloperoxidas
concentr
quantit
immunometr
assay
use
biotinyl
antibodi
avidinalkalin
phosphatas
label
cappel
organon
teknika
corp
west
chester
pa
detect
standard
purifi
human
leukocyt
myeloperoxidas
bovin
milk
lactoperoxidas
sigma
chemic
co
use
immunogen
rais
antibodi
bovin
milk
lactoperoxidas
human
salivari
peroxidas
immunolog
crossreact
lactoferrin
level
determin
immunometr
assay
use
biotinyl
antibodi
avidinbiotinperoxidas
complex
vector
laboratori
burlingam
calif
human
colostr
lactoferrin
sigma
chemic
co
purifi
affin
chromatographi
use
immunogen
rais
antibodi
standard
assay
total
concentr
salivari
iga
igg
igm
assay
captur
antibodi
type
enzym
immunoassay
describ
lehtonen
et
al
rabbit
antiiga
igg
igm
antibodi
heavychain
specif
rabbit
antiiga
antiigg
antiigm
correspond
reagent
conjug
horseradish
peroxidas
dakoimmunoglobulin
copenhagen
denmark
human
control
sera
norpartigen
behringwerk
ag
marburg
germani
substrat
enzym
immunoassay
sigma
chemic
co
absorb
lactoferrin
immunoglobulin
peroxidas
assay
detect
automat
spectrophotomet
titertek
multiscan
eflab
oy
helsinki
finland
differ
placebo
experiment
group
analyz
mean
student
test
differ
within
group
mean
analyz
mean
student
pair
test
p
valu
less
consid
statist
signific
placebo
group
cc
group
analyz
studi
effect
common
cold
defens
factor
flow
rate
paraffinstimul
whole
saliva
decreas
period
common
cold
increas
infect
day
howev
chang
statist
signific
tabl
ii
innat
host
defens
factorslysozym
lactoferrin
myeloperoxidas
salivari
peroxidasewer
affect
common
cold
result
obtain
total
salivari
protein
content
immunolog
salivari
defens
factor
repres
studi
concentr
total
iga
igg
igm
iga
increas
significantli
p
cc
group
day
day
tabl
ii
data
analyz
output
secret
protein
salivari
gland
mgmin
effect
common
cold
could
observ
data
shown
howev
cc
group
rel
proport
proteintot
amount
protein
salivari
peroxidas
increas
significantli
p
day
iga
increas
significantli
p
day
tabl
iii
salivari
flow
rate
significantli
p
lower
day
day
ft
group
innat
salivari
host
defens
factor
affect
medic
tabl
ii
comparison
valu
day
iga
increas
ft
group
day
day
p
tabl
ii
also
tendenc
toward
increas
secret
igg
igm
tabl
ii
ft
group
output
lactoferrin
mgmin
significantli
p
lower
day
day
fluticason
propion
medic
affect
output
salivari
paramet
either
innat
acquir
rel
amount
iga
secret
tabl
iii
increas
significantli
day
p
day
p
statist
differ
could
found
group
respect
salivari
flow
rate
innat
salivari
defens
factor
lysozym
lactoferrin
myeloperoxidas
salivari
peroxidas
tabl
ii
secret
total
protein
content
saliva
howev
significantli
lower
ft
group
cc
group
day
p
day
p
day
p
rel
amount
lysozym
secret
lysozymetot
protein
content
higher
day
p
day
p
ft
group
cc
group
tabl
iii
neither
common
cold
fluticason
propion
treatment
effect
rel
amount
secret
igg
igm
immunoglobulin
knowledg
previou
studi
effect
common
cold
secret
rate
composit
human
saliva
studi
show
salivari
flow
rate
lowest
day
suggest
onset
common
cold
may
transient
stimul
flow
rate
use
local
administ
fluticason
propion
appear
affect
salivari
flow
rate
secret
rate
rel
amount
secret
protein
suggest
mean
assess
contribut
synthes
salivari
protein
independ
flow
rate
approach
use
mani
studi
analyz
effect
system
factor
synthesi
salivari
protein
subsequ
saliva
composit
analysi
data
base
output
rate
indic
system
effect
either
fluticason
propion
common
cold
nonimmun
defens
factor
analysi
rel
amount
secret
protein
show
immunoglobulin
especi
iga
contribut
higher
degre
protein
total
protein
content
whole
saliva
patient
common
cold
studi
group
ingredi
medic
benzalkon
hydrochlorid
may
effect
could
control
studi
antibodi
virus
bacteria
like
emerg
common
mucos
immun
system
total
concentr
salivari
iga
rel
amount
iga
significantli
elev
day
onset
common
cold
increas
evid
day
common
cold
differ
ft
cc
group
could
notic
therefor
salivari
iga
respons
probabl
induc
virus
treatment
common
cold
fluticason
propion
neg
influenc
defens
factor
although
common
cold
follow
significantli
enhanc
mucos
iga
respons
clear
whether
effect
clinic
import
iga
one
major
factor
elimin
eg
aggreg
bacteria
virus
mucos
surfac
effect
therefor
like
import
vivo
howev
studi
actual
microbi
chang
need
elucid
real
biolog
signific
observ
conclus
humor
immunolog
defens
factor
human
whole
saliva
activ
common
cold
neither
common
cold
nasal
administ
topic
activ
glucocortico
